Creatine for Women During and After Menopause

Creatine has moved from the gym shelf to menopause forums, podcasts and wellness newsletters aimed at women in midlife. It’s had a busier few years than most supplements. Humanic Blue separates what’s actually been tested in women from what’s been extrapolated from men, mice or marketing—a useful distinction if you’re considering creatine for women during and after menopause.

Here’s how the research shakes out. A 2026 meta-analysis—a study that combines results from several trials—of seven trials in postmenopausal women found small average gains in lean mass and leg-press strength, while bone density did not improve overall. The apparent benefits came mainly from trials pairing at least 5 grams a day with resistance training, but that subgroup result is exploratory rather than proof of a universal dose. One newer, eight-week trial in perimenopausal or menopausal women reported a reaction-time and brain-creatine signal from one low-dose specialty formulation; it did not establish relief from hot flashes or sleep problems. No trial shows that creatine helps women live longer. Several researchers behind the evidence have creatine-industry relationships, which matters when weighing modest and still-uncertain effects.

Below, we work through the four claims together: what’s been tested, and the funding context.

Claim 1: Does creatine help muscle and strength?

The muscle-and-strength claim has been tested in several trials. A 2026 systematic review and meta-analysis in the Journal of the International Society of Sports Nutrition pooled seven randomized trials in postmenopausal women, average age about 62. The trials lasted from about three months to two years.

Compared with placebo, creatine increased lean mass—body tissue other than fat—by an average of 0.37 kg and the weight women could press on a leg-press machine by 7.5 kg. The apparent gains occurred in subgroup analyses of trials using at least 5 g/day with resistance training; trials using 3 g/day or less without training did not show measurable effects. Because these were subgroup findings across only seven trials, they are better treated as a pattern to test than a settled dose rule. Adverse events were generally mild and similar to placebo, and the reported kidney measures did not differ between groups.

For scale, 0.37 kg is less than a pound of lean mass. The pooled participants averaged about 62 years old, and the trials lasted from about three months to two years, so the estimate does not tell us what every woman in perimenopause or later life should expect. Why lean mass falls during menopause, and what else protects it, is covered in Protect Muscle During Menopause.

Claim 2: Bone

Creatine is often marketed for bone after menopause. The same meta-analysis found no significant overall improvement in bone mineral density. That leaves a possible bone benefit unproven rather than proving that no formulation, dose or longer exposure could ever help.

The two long trials behind that conclusion, one with training and one without, are covered in detail in Creatine After 50. Neither improved bone density; the training trial reported changes in hip-bone shape and structure that the researchers interpreted as favorable, a secondary finding rather than evidence of fewer fractures.

What separates a finding about muscle strength from evidence about bone density?

Claim 3: What about mood and cognition?

Creatine is studied for the brain because the brain also uses the creatine energy system. The findings most relevant to women do not all point in the same direction.

A 2012 trial in the American Journal of Psychiatry randomly assigned women with major depression to the antidepressant escitalopram plus either 5 grams of creatine a day or placebo for eight weeks. Depression scores improved faster with creatine, beginning at week two. Overall adverse-event frequency was similar, although discontinuation was higher in the creatine group (32.0% versus 18.5%). This was a small trial of creatine added to an antidepressant, not a menopause trial, and it does not justify using creatine in place of depression care.

For memory and thinking, the direct evidence in older women includes a null result. A 24-week randomized trial assigned apparently healthy older women to four small groups: creatine with or without strength training, or placebo with or without training. Strength training improved strength and depressive-symptom scores, but adding creatine did not significantly improve the measured cognitive or emotional outcomes.

A newer eight-week randomized trial enrolled apparently healthy perimenopausal or menopausal women, with a mean age of about 50, across three low-dose specialty-creatine groups and placebo. The 1,500 mg/day creatine-hydrochloride group had a better reaction-time result and higher frontal-brain creatine than placebo. With roughly nine participants per arm, multiple formulations and outcomes, and no conventionally significant mood result, this is a signal that needs independent replication—not established cognitive treatment.

How much of the mood and cognition evidence directly addresses the menopause transition?

Claim 4: Does creatine ease hot flashes, sleep or other symptoms?

This section is short for a reason. The small specialty-creatine trial enrolled perimenopausal or menopausal women and tracked clinical outcomes, but its abstract does not report a benefit for hot flashes, night sweats or sleep. We found no randomized evidence establishing creatine as a treatment for those symptoms. Treatments supported by menopause-specific evidence, including hormone therapy for appropriate candidates, are covered in Menopause and Longevity.

The funding context

Every research story has a backstory. Creatine research has close ties to industry, and the key women’s-health papers are no exception. The 2026 meta-analysis reported no conflict specific to that review, but it also disclosed that one author chairs an Alzchem-supported scientific advisory board and another leads a society that sometimes receives funding from creatine companies. Alzchem contributed to the publication fee, and the review was not prospectively registered.

That doesn’t make the findings wrong. The meta-analysis pooled randomized trials and reported null results for bone. It’s a reason to weigh the modest size of the effects and look for independent replication.